The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure identifies tafamidis as a disease-modifying therapy for transthyretin amyloid cardiomyopathy (ATTR-CM) with demonstrated efficacy in improving cardiovascular outcomes. Specifically, based on the pivotal ATTR-ACT randomized clinical trial, tafamidis significantly reduced all-cause mortality (29.5% vs 42.9%) and cardiovascular-related hospitalizations (0.48 vs 0.70 per year) over 30 months, while also attenuating decline in functional capacity and quality of life. The guideline notes that tafamidis stabilizes transthyretin and prevents further amyloid deposition, with greater benefit when initiated earlier in the disease course, although it does not reverse existing amyloid burden . Safety data indicate that adverse event rates are comparable to placebo, with no significant treatment-related safety signals identified in clinical trials and long-term extension analyses. From a guideline perspective, tafamidis is described as the only therapy shown to improve cardiovascular outcomes in ATTR-CM and is recommended for appropriate patients with symptomatic disease (typically NYHA class I–III), while benefit has not been demonstrated in advanced (class IV) heart failure or certain high-risk populations. Despite its clinical efficacy, the guideline also highlights economic considerations, noting that tafamidis is associated with high cost and low value based on cost-effectiveness analyses. Overall, the guideline supports tafamidis as an evidence-based, outcome-improving therapy for ATTR-CM with a favorable safety profile but acknowledges limitations related to patient selection and cost. [1]
The 2024 NICE technology appraisal guidance recommends tafamidis, within its marketing authorization, as an option for treating wild-type or hereditary ATTR-CM in adults, provided it is supplied under the agreed commercial arrangement. NICE states that ATTR-CM is a progressive, life-limiting condition for which treatment options have largely been limited to symptom management and best supportive care, and identifies tafamidis as the first treatment for ATTR-CM that aims to treat the condition itself. The efficacy evidence considered by the committee was based primarily on the phase 3 ATTR-ACT trial and its open-label long-term extension; NICE reports that the main clinical trial showed tafamidis reduced deaths and hospitalizations from conditions affecting the heart and blood vessels versus placebo, and that longer-term evidence reduced uncertainty regarding survival and treatment duration, although NICE also noted that not all scope-specified updated outcomes, including cardiovascular-related mortality and hospitalizations, were presented at the 84-month follow-up. With respect to safety, NICE notes that ATTR-ACT evaluated the effectiveness, safety, and tolerability of tafamidis versus placebo and that updated adverse event data from the long-term extension were submitted, but the guidance does not report detailed adverse event rates or specific new safety signals in the text provided. From a national guidance perspective, NICE concluded that tafamidis was cost effective versus best supportive care and therefore recommended it for NHS use in England; implementation requirements state that NHS England and integrated care boards should fund access within 30 days of publication because tafamidis had been available through the early access to medicines scheme, and the NHS in Wales must usually provide funding and resources within 2 months of first publication of the final draft guidance. [2]
A 2024 ICER final evidence report on disease-modifying therapies for ATTR-CM states that, in the pivotal ATTR-ACT trial, tafamidis reduced all-cause mortality versus placebo (hazard ratio [HR] 0.67; 95% CI 0.49-0.94), with survival curves diverging at approximately 18 months, reduced cardiovascular-related hospitalizations (0.49 vs 0.70 hospitalizations per year; relative risk ratio 0.70, 95% CI 0.57-0.85), and slowed decline in functional status and quality of life, including a 75.6 m between-group difference in 6-minute walk distance and a 13.4-point difference in KCCQ-OS at 30 months; longer-term follow-up is described as showing a 41% lower risk of all-cause mortality with continuous tafamidis treatment, and ICER judged tafamidis to have high certainty of substantial net health benefit in the original trial population and, in a contemporary population, high certainty of at least small net health benefit with moderate certainty of substantial net health benefit. Safety was described as favorable and comparable to placebo and to the 20 mg dose, with most adverse events mild or moderate; the most common adverse events were diarrhea (8%) in the 80 mg group and urinary tract infection (5.7%) in the 20 mg group, and dose reductions were uncommon (1.1% with tafamidis 80 mg vs 2.3% with placebo). Regarding guidelines, the report summarizes that the 2023 World Heart Federation consensus notes strong evidence from ATTR-ACT supporting tafamidis and highlights access and cost barriers; the 2023 ACC Expert Consensus Decision Pathway describes tafamidis as effective with a favorable side-effect profile but identifies cost and copayment-navigation barriers; the 2022 AHA/ACC/HFSA heart failure guideline recommends tafamidis for select patients with wild-type or hereditary ATTR-CM and NYHA class I-III symptoms to reduce cardiovascular morbidity and mortality (Class 1, Level B); and the 2020 Canadian Cardiovascular Society/Canadian Heart Failure Society position statement notes the efficacy of tafamidis in ATTR-ACT and states that treatment choice in patients with mixed cardiac and neurologic phenotypes should be individualized by interdisciplinary teams. [3]
These phase 3 ATTR-ACT and long-term extension (LTE) analyses in transthyretin amyloid cardiomyopathy report that tafamidis was associated with reductions in mortality, cardiovascular-related hospitalizations, functional decline, and biomarker progression, with a safety profile described as comparable to placebo. In ATTR-ACT, tafamidis 80 mg and 20 mg both significantly reduced the composite of all-cause mortality and cardiovascular-related hospitalizations versus placebo (p= 0.0030 and p= 0.0048, respectively), reduced decline in 6-minute walk test distance and KCCQ-OS scores (p<0.0001 for both doses), and lowered rates of cardiovascular-related hospitalizations; all-cause mortality was significantly reduced with 80 mg (hazard ratio [HR] 0.69; 95% CI 0.487 to 0.979; p= 0.0378), while 20 mg showed a non-significant reduction (HR 0.715; p= 0.1564). Tafamidis 80 mg also demonstrated greater attenuation of increases in NT-proBNP and troponin I compared with placebo, with a significant difference versus 20 mg for NT-proBNP. Long-term data showed that patients initially treated with tafamidis had lower all-cause mortality than those initially receiving placebo and later transitioning to tafamidis (HR 0.59; 95% CI 0.44 to 0.79; p<0.001) over a median follow-up of approximately 58 months, with consistent effects across genotype and NYHA class subgroups. Across studies, tafamidis was reported as generally well tolerated, with similar rates of adverse events, serious adverse events, and discontinuations compared with placebo, and no new safety concerns identified in the LTE. [4], [5]